Trial Profile
Phase II Study of CHOP[cyclophosphamide + vincristine + doxorubicin + prednisone]/Rituxan Plus VELCADE [bortezomib] in Mediastinal Large B-Cell Lymphoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Prednisone (Primary) ; Rituximab (Primary) ; Vincristine (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 06 Oct 2009 Actual number of patients (3) added as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 06 Jun 2008 Status changed from in progress to completed.